{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 440816974
| IUPAC_name = (1''S'',5''R'',13''R'',17''S'')- 10,17-dihydroxy- 4-(prop-2-en-1-yl)- 12-oxa- 4-azapentacyclo [9.6.1.0<sup>1,13</sup>.0<sup>5,17</sup>.0<sup>7,18</sup>] octadeca- 7(18),8,10-trien- 14-one
| image = Naloxone.svg
| image2 = Naloxone-3D-balls.png

<!--Clinical data-->
| tradename = Narcan、Evzio
| Drugs.com = {{drugs.com|monograph|naloxone-hydrochloride}}
| pregnancy_AU = B1
| pregnancy_US = C<ref name=AHFS2015/>
| legal_AU = S4
| legal_UK = POM
| routes_of_administration = 氣管、鼻、[[靜脈注射|靜脈注射]]、[[肌肉注射|肌肉注射]]

<!--Pharmacokinetic data-->
| bioavailability = 2%（口服，吸收率90%，但[[首过效应|首过效应]]很強）
| metabolism = [[肝|肝]]
| onset       = 2 min（IV），5 min (IM)<ref name=AHFS2015/>
| elimination_half-life = 1-1.5 h
| duration_of_action= 30 to 60 min<ref name=AHFS2015/>
| excretion = 尿液、膽道

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 465-65-6
| ATC_prefix = V03
| ATC_suffix = AB15
| PubChem = 5284596
| IUPHAR_ligand = 1638
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01183
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447644
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 36B82AMQ7N
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08249
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7459
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 80

<!--Chemical data-->
| C=19 | H=21 | N=1 | O=4
| molecular_weight = 327.37 g/mol
| smiles = O=C1[C@@H]2OC3=C(O)C=CC4=C3[C@@]2([C@]5(CC1)O)CCN(CC=C)[C@@H]5C4
| InChI = 1/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UZHSEJADLWPNLE-GRGSLBFTSA-N
| synonyms = <small>17-allyl- 4,5α-epoxy- 3,14-dihydroxymorphinan- 6-one</small>
}}

<!-- Medical uses -->
'''納洛酮'''（{{lang|en|Naloxone}}），又常以[[商品名|商品名]]「'''Narcan'''」販售。該藥物可以緩解攝入過量[[鴉片類藥物|鴉片類藥物]]所造成的影響<ref name=AHFS2015/>。納洛酮可以與鴉片類藥物混入同一藥品中，以減少誤用時中毒的風險。納洛酮常被製成鼻噴劑<!-- <ref name=AHFS2015/>-->。若[[靜脈注射|靜脈注射]]給藥，藥效會於兩分鐘內作用；肌肉注射則約為五分鐘內作用<ref name=AHFS2015/><ref>{{cite book|last1=Roberts|first1=James R.|title=Roberts and Hedges' clinical procedures in emergency medicine|date=2014|publisher=Elsevier Health Sciences|location=London|isbn=9781455748594|page=476|edition=6|url=https://books.google.ca/books?id=slyLreFkHuIC&pg=PA476}}</ref>。納洛酮的藥效約會維持1至1.5小時左右<ref>{{cite book|last1=Bosack|first1=Robert|title=Anesthesia Complications in the Dental Office|date=2015|publisher=John Wiley & Sons|isbn=9781118828625|page=191|url=https://books.google.ca/books?id=Rn51BwAAQBAJ&pg=PA191}}</ref>，由於鴉片類藥物作用的時間較納洛酮長，因此在以納洛酮進行治療時必須多次給藥<ref name=AHFS2015/>。

<!-- Side effects and mechanism -->
在成癮者戒斷鴉片類藥物的過程中，有些患者會出現[[藥物戒斷|戒斷症]]。症狀包含躁動、噁心、嘔吐、[[心跳過速|心跳過快]]和盜汗等等<!-- <ref name=AHFS2015/> -->。因此可以在戒斷初期每數分鐘給予納洛酮，直到其症狀舒緩<!-- <ref name=AHFS2015/> -->。有心臟病史的患者宜慎用，因其可能會引發心臟疾病<ref name=AHFS2015>{{cite web|title=Naloxone Hydrochloride|url=http://www.drugs.com/monograph/naloxone-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=Jan 2, 2015|archive-date=2015-01-02|archive-url=https://web.archive.org/web/20150102115454/http://www.drugs.com/monograph/naloxone-hydrochloride.html|dead-url=no}}</ref>。孕婦在經過小規模人體測試後，目前顯示沒有不良影響<ref name=TGA2014>{{cite web|title=Prescribing medicines in pregnancy database|url=http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|work=Australian Government|accessdate=22 April 2014|date=3 March 2014|archive-date=2014-04-08|archive-url=https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|dead-url=no}}</ref>。納洛酮為一種競爭性[[受體拮抗劑|受體拮抗劑]]<!-- <ref name=AHFS2015/> -->，可與鴉片類藥物競爭中樞神經和呼吸系統的受體，以舒緩症狀<ref name=AHFS2015/>。

<!-- History, society and culture -->
納洛酮於1961年{{le|傑克·菲什曼|Jack Fishman}}、Mozes J. Lewenstein，和{{le|第一三共株式會社|Daiichi_Sankyo|三共株式會社}}取得專利<!-- <ref name="nyti_Jack"/> -->，並於1971年受[[美國食品藥品監督管理局|美國食品藥品監督管理局]]核准成為治療鴉片過量症狀的藥物<ref name="nyti_Jack">{{Cite web| title = Jack Fishman Dies at 83; Saved Many From Overdose| last = Yardley | first = William| work = New York Times| date = 14 December 2013| accessdate = 2015-07-06| url = http://www.nytimes.com/2013/12/15/business/jack-fishman-who-helped-develop-a-drug-to-treat-overdoses-dies-at-83.html?_r=0}}</ref>。該藥也列名於[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]，為基礎醫療的必備藥物之一<ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013|archive-date=2014-04-23|archive-url=https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|dead-url=no}}</ref>。納洛酮已經成為[[通用名藥物|通用名藥物]]，價格不貴<ref name=AHFS2015/><ref>{{cite book|last1=Hamilton|first1=Richard J.|title=Tarascon pocket pharmacopoeia : 2014 classic shirt-pocket edition|date=2013|publisher=Jones & Bartlett Learning|location=Sudbury|isbn=9781284053982|page=174|edition=28|url=https://books.google.ca/books?id=y0KFAgAAQBAJ&pg=PA174}}</ref>，每劑的批發價價格區間約為0.50至5.30美元之間<ref>{{cite web|title=Naloxone HCL|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=NAL04A&s_year=2014&year=2014&str=0%2E4%20mg%2Fml&desc=Naloxone%20HCl&pack=new&frm=AMPOULE&rte=INJ&class_code2=04%2E2%2E&supplement=&class_name=%2804%2E2%2E%29Specific%20antidotes%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=13 August 2015}}{{Dead link|date=2018年6月 |bot=InternetArchiveBot |fix-attempted=no }}</ref>。

==參考資料==
{{reflist}}

{{解毒剂}}
{{止痛药}}
{{Sigmaergics}}
{{Emergency medicine}}

[[Category:醇|Category:醇]]
[[Category:烯烃|Category:烯烃]]
[[Category:酮|Category:酮]]
[[Category:吗喃类|Category:吗喃类]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]